Emergence of psychedelic-assisted psychotherapy (PAP) / Rising approval of additional psychedelic drugs / Rising popularity of psilocybin

DUBLIN, March 25, 2022 /PRNewswire/ — The “Global Psychedelic Drug Market: Analysis by Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson’s Disease, OUD, Alzheimer’s Disease, AUD, TUD, Eating Disorder, and Narcolepsy) Size and Trends with Impact of Covid-19 and upward forecast until 2025” Report has been added to ResearchAndMarkets.com offering.

Research and Markets Logo

Research and Markets Logo

The report provides an in-depth analysis of the global psychedelic drug market by value, indication, etc. The report also provides a detailed analysis of the impact of COVID-19 on the psychedelic drugs market.

Psychedelic drugs are a group of substances that can induce and enhance sensory perceptions, thoughts, and energy levels. Psychedelic drugs were heavily used in the 1960s, but use stopped mainly for political reasons. Recently, however, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic stress disorder, etc.

Some psychedelic drugs are extracted from plants or fungi, and some are synthetic (man-made). These medications are now considered effective for patients with treatment-resistant depression, as they are fast-acting and long-lasting.

The most common psychedelic substances include: ketamine, psilocybin, ibogaine, LSD, dimethyltryptamine (DMT), or MDMA. Most of the psychedelic drugs in development are targeted at mental and/or behavioral health indications. This is an area with significant unmet need.

The psychedelic drug market can be segmented based on indication (ADHD, MDD, bipolar, migraine, anxiety, Parkinson’s disease, OUD, Alzheimer’s disease, AUD, TUD, eating disorder, and narcolepsy); and type of drug (lysergic acid diethylamide (LSD), ketamine, psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and others).

The global market for psychedelic drugs has increased significantly in recent years and projections are made that the market will increase in the coming years. The psychedelic drug market is expected to increase due to rising prevalence of depression and mental disorders, regulatory reforms, psychedelic-related developments, changing perceptions, less serious and profitable side effects, etc. FDA approval, the early stage in the life cycle of the psychedelic industry, the stigma associated with psychedelic drug use, etc.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. The growth of the overall global psychedelic drug market has also been forecast up to the period 2025, taking into account past growth patterns, growth drivers, and current and future trends.

The global psychedelic drug market remains early in its life cycle, with most companies currently developing their marketing strategy. Psychedelics market players are involved in clinical trials of several psychedelic drugs to address mental health, which continues to present a significant unmet need.

The key players of the psychedelic drugs market are COMPASS Pathways Plc, Mind Medicine (MindMed) Inc., Numinus Wellness Inc. and Johnson & Johnson are also described with their financial information and their respective business strategies.

Key Topics Covered:

1. Executive Summary

2. Introduction
2.1 Psychedelic drugs: an overview
2.1.1 History of psychedelic drugs
2.1.2 Advantages and disadvantages of psychedelic drugs
2.1.3 Main types of psychedelic drugs
2.1.4 Possible treatment indications for psychedelic molecules
2.1.5 Psychedelic classification
2.2 Psychedelic Drug Segmentation: An Overview
2.2.1 Psychedelic Drugs Segmentation by Indication
2.2.2 Psychedelic Drugs Segmentation by Type of Drug

3. World market analysis
3.1 Global Psychedelic Drugs Market: An Analysis
3.1.1 Global Psychedelic Drugs Market by Value
3.1.2 Global Psychedelic Drugs Market by Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson’s Disease, OUD, Alzheimer’s Disease, AUD, TUD, Eating Disorder, and Narcolepsy)
3.2 Global Psychedelic Drugs Market: Indications Analysis
3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Psychedelic Drugs Market by Value
3.2.2 Global Major Depressive Disorder (MDD) Psychedelic Drugs Market by Value
3.2.3 Global Bipolar Disorder Psychedelic Drugs Market by Value
3.2.4 Global Psychedelic Drugs for Migraine Market by Value
3.2.5 Global Anxiety Psychedelic Drugs Market by Value
3.2.6 Global Parkinson’s Disease Psychedelic Drugs Market by Value
3.2.7 Global Opioid Use Disorder (OUD) Psychedelic Drugs Market by Value
3.2.8 Global Alzheimer’s Disease Psychedelic Drugs Market by Value
3.2.9 Global Alcohol Use Disorder (AUD) Psychedelic Drugs Market by Value
3.2.10 Global Psychedelic Drugs for Tobacco Use Disorder (TUD) Market by Value
3.2.11 Global Psychedelic Eating Disorder Drugs Market By Value
3.2.12 Global psychedelic drug market for narcolepsy by value

4. Impact of COVID-19
4.1 Impact of COVID-19
4.1.1 Impact of COVID-19 on the Health Sector
4.1.2 Impact of COVID-19 on the psychedelic drug industry

5. Market dynamics
5.1 Engine of growth
5.1.1 Increased prevalence of depression and mental disorders
5.1.2 Regulatory reforms
5.1.3 Developments related to psychedelics
5.1.4 Changing perceptions
5.1.5 Minor side effects and cost-effective
5.2 Challenges
5.2.1 Uncertainty around obtaining FDA approval
5.2.2 Early life cycle of the psychedelics industry
5.2.3 Stigma associated with the use of psychedelic drugs
5.3 Market trends
5.3.1 Increasing approval of additional psychedelic drugs
5.3.2 Growing popularity of psilocybin
5.3.3 Increasing number of potential candidates for Breakthrough Therapy Designation (BTD)
5.3.4 Growing popularity of microdosing psychedelics
5.3.5 Emergence of psychedelic-assisted psychotherapy (PAP)
5.3.6 Increased potential treatment indications for psychedelic drugs

6. Competitive landscape
6.1 Global Psychedelic Drugs Market Players by Drug TAM
6.2 Global Psychedelic Drugs Market Players by Psychedelic Related Businesses
6.3 Global Psychedelic Drugs Market Players by Clinical Trials Related to Psychedelics
6.4 Global Psychedelic Drugs Market Players by Breakthrough Therapy Designations (BTD) for Psychedelic Substances

7. Company profiles
7.1 General description of the business
7.2 Business strategy

For more information on this report, visit https://www.researchandmarkets.com/r/qde2z5

Media Contact:

Research and Markets
laura woodSenior manager
press@researchandmarkets.com

For business hours EST call +1-917-300-0470
For US/Canada call toll free +1-800-526-8630
For GMT business hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

cision

cision

See original content:https://www.prnewswire.com/news-releases/global-psychedelic-drugs-markets-2022-2025-emergence-of-psychedelic-assisted-psychotherapy-pap–rising-approval-for-additional-psychedelic-drugs –growing-popularity-of-psilocybin-301510800.html

SOURCE Research and Markets

Previous post How to prepare for a sudden financial hardship
Next post Column: Global diesel shortage drives up oil prices
%d bloggers like this: